Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer
KCT0003249Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib, paclitaxel in gastric cancer (GC), sponsored by AstraZeneca. Started Nov 2018; status: recruiting.
02
Drugs
durvalumabolaparibpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0003249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003249.